DarioHealth Q4 Revenue Hits $5.2M; GAAP Margin Improves to 57%
DarioHealth’s Q4 revenue rose sequentially to $5.2 million while full-year revenue totaled $22.4 million, down from $27.0 million in 2024 due to a single legacy client nonrenewal. The company reported GAAP gross margin of 57% and cut non-GAAP operating expenses by 28%, with a $122 million B2B2C pipeline and $12.9 million in ARR bookings.
1. Fourth Quarter and Full-Year Results
DarioHealth reported Q4 2025 revenue of $5.2 million, up from $5.0 million in Q3, while full-year revenue reached $22.4 million versus $27.0 million in 2024, reflecting a scope change and nonrenewal from one legacy client unrelated to demand.
2. Expense Reduction
Non-GAAP operating expenses in Q4 fell 28% year-over-year to $9.0 million, the lowest run-rate since the Twill acquisition, contributing to improved operating losses on both GAAP and non-GAAP bases.
3. ARR Bookings and Pipeline
The 2025 sales season secured $12.9 million in contracted and late-stage annual recurring revenue expected to convert in 2026–2027, and the commercial pipeline expanded to $122 million across more than 200 B2B2C opportunities.
4. Commercial and Product Highlights
DarioHealth signed 85 new agreements in 2025 with average contract sizes 2x–10x historical levels, saw 36% growth in its MSK B2C product in Q4, and advanced its AI-driven platform powered by 13 billion real-world data points alongside its GLP-1 digital health solution.